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Abstract 
Aims. There is little information on the familial nature of dyslipidemias in the Spanish population. This knowledge 
could have potential diagnostic and treatment implications. The objective of the GALIPEMIAS study was to 
determine the prevalence of familial dyslipidemia in Galicia, as well as determine the degree of lipid control in the 
participants. Prevalence of atherosclerotic cardiovascular disease (ASCVD) was also estimated. This paper presents 
the design, methodology and selected preliminary results. 
Methodology. A cross‐sectional study was performed in the population aged ≥18 years using cluster sampling and 
then random sampling. A sample of 1000 subjects was calculated and divided into three sequential phases with a 
specific methodology for each one. Phase I: selection of subjects from the general population and collection of 
informed consent documents; Phase II: collection of data from the digital clinical history to select subjects with 
dyslipidemia according to study criteria; Phase III: personal interview, blood analysis, family tree, and definitive 
diagnosis of dyslipidemia. Prevalence of different diseases and active medication was analysed. Corrected prevalence 
(to the reference population) of different risk factors and ASCVD was estimated. 
Results. Phase I participation was 89.5%. We extracted complete information from 93% of the participants (Phase II). 
According to the study′s own criteria, 56.5% (n = 527) of the participants had some form of dyslipidemia and almost 
33.7% of them had familial dyslipidemia with autosomal dominant inherit pattern. The corrected prevalence of 
ASCVD was 5.1% (95% CI 3.1‐7.2). 
Conclusions. Dyslipidemia was the most prevalent cardiovascular risk factor in our population with an autosomal 
dominant inheritance pattern in one out of every three dyslipidemia cases. Approximately, 5.1% of the sample 
population aged ≥18 has suffered an episode of ACVD. 
What's known 
Cardiovascular diseases are an important health problem. Many of them are because of atherosclerosis and its 
complications and are grouped under the name of atherosclerotic cardiovascular diseases (ASCVD). 
More than half of the adult Spanish population has dyslipidemia and an unknown proportion of these cases are 
because of inherited disorders. The natural history of the dyslipidemia is linked to the development of ASCVD. The 
proportion of patients with ASCVD and with familial dyslipidemia is unknown. 
What's new 
We present, in detail, the methodology used on the GALIPEMIAS study (prevalence of familial dyslipidemia in an 
area of northwest Spain) with a sample of 1003 participants, describe the current cardiovascular situation and analyse 







In Spain, cardiovascular diseases are the leading cause of hospitalisation and death, cause high costs 
in health services
1,2
 and rank third as a cause of disability.
3
 Many cardiovascular diseases are because of 
the development of atherosclerosis and its complications and can be grouped under the atherosclerotic 
cardiovascular diseases (ASCVD) because they can coexist in the same patient,
4
 share similar 
cardiovascular risk factors (diabetes mellitus, hypertension, smoking and dyslipidemia) and receive 
similar medical treatment regardless of the vascular territory involved.
5
 Under this heading, almost all 
cases of coronary heart disease (CHD) or peripheral arterial disease (PAD) and many types of strokes 
(CeVD) are included. However, no studies have evaluated the prevalence of ASCVD in our country.  
 
With the term “dyslipidemia”, we mean quantitative alterations of plasma lipids that include increase 
in total cholesterol (TC >200 mg/dL), cholesterol linked to low‐density lipoprotein (LDL‐
C > 130 mg/dL), triglycerides (TG; >150 mg/dL) or decrease in cholesterol linked to high‐density 
lipoprotein (LDH‐C < 40 mg/dL in men or LDH‐C < 50 mg/dL in women). Under this approach, more 
than half of the Spanish not institutionalised adult population has dyslipidemia.
6,7
 An unknown proportion 
of these cases are because of inherited disorders or familial dyslipidemia, part of which are familial 
dyslipidemia with an autosomal dominant inheritance pattern (FDAD) as familial hypercholesterolaemia 
(FH), familial combined hyperlipidaemia (FCH) or familial hypertriglyceridaemia (FHTG). The natural 
history of these familial dyslipidemias with FDAD is linked to the development of ASCVD
8,9
 and even 
premature CHD.
10
 However, the proportion of patients with ASCVD who have some form of familial 
dyslipidemia with FDAD is unknown.  
 
We designed the population‐based GALIPEMIAS study (prevalence of family dyslipidemia in 
Galicia) to answer these questions in our community. We present, in detail, the methodology and analysis 
used to determine the prevalence of ASCVD and familial dyslipidemias with autosomal dominant 
inheritance pattern. 
2 METHODS 
A cross‐sectional study was carried on a population living in the autonomous community of Galicia 
(northwest Spain) with an age greater than or equal to 18 years and with a health card (with provision of 
health services supported by the public health administration). The public health administration in Galicia 
promoted the study. 
 
Sampling was performed by clusters. All the first‐level clusters (health district) were represented and 
were assigned a sample size proportional to cluster size. Estimating a joint prevalence of FH, FCH and 
FHTG of 3.5% with a confidence interval of 95% and considering a design effect of 1.7% because of the 
type of sampling, a sample of 1000 participants was calculated. 
 
Selection of sample: 70 municipalities of the eight community health areas were selected (by 
feasibility criteria). A minimum set of personal data (sociodemographic variables and telephone numbers) 
was acquired from the public health administration in Galicia (1.4 million people representing 61.3% of 
the Galician population). Over 99% of the population living in these municipalities had health cards. 
From this database, participants and adequate substitutes to replace mistakes and nonparticipation were 
selected randomly and proportionally to size of the area. 
 
Field work was done in three successive phases to optimise data collection. The detailed methodology 
of each phase is explained in Table 1. In general, Phase I (telephone survey) was used to recruit 
participants and obtain informed consent; patients with dyslipidemia were identified in Phase II (through 
digital clinical history); and Phase III (physical examination) was used to characterise familial 
dyslipidemia with FDAD (through family trees).  
  
Table 1. Methodology used in each phase 
 
Phase I Phase II Phase III 
    
Goals  Recruit study subjects. 
 Explain the phases, the 
study objectives and a 
possible personal 
interview. 
 Obtaining oral informed 
consent to access to DCH 
and record it. 
 Collect oral health 
information from the 
participant 
Collect useful health information to 
filter subjects with possible or safe 
dyslipidemia under the study criteria 
 Collect documentary evidence. 
 Diagnose the dyslipidemia 
Procedures Phone callsa Individual review of the DCH  Citation via phone calla and/or letter.  
 Physical examination, personal 
interview, family tree (first degree 
relatives: father, mother, 
brothers/sisters, sons/daughters) and 
a blood analysis 
Source(s) of 
information 
Participant IANUS (online platform of DCH) Participant with possible or safe 
dyslipidemia. IANUS (evaluation of 
relatives) 
Who collects the 
data? 
Trained staff (nonclinical) 13 researchersb 13 researchersb 
Inclusion/exclusion 
criteria 
Exclusion criteria:  
 
 Inability to collaborate 
(death, neurodegenerative 
diseases, admitted to 
geriatric hospitals, 
embarked, residents in 
another autonomous 
community). 
 Oral manifestation of not 
wishing to participate 
Inclusion criteria: All subjects with 
oral consent in Phase I 
Inclusion criteria:  
 
 All subjects that in Phase II meet one 
or more of the following criteria: any 
blood analysis (old/current) with TC 
≥240 mg/dL or TG ≥150 mg/dL or 
LDL‐C ≥ 160 mg/dL or HDL‐
C < 50 mg/dL (women)/<40 mg/dL 
(men). 
 Intake of lipid‐lowering drugs 
recorded in DCH 
What information is 
collected? 
 Oral informed consent 
recorded. 
 Information provided by 
the participant (smoking 
habits, history of disease 
and current drug intake) 
 From the DCH (history of disease, 
cardiovascular risk factors, drug 
intake, presence of different 
conditions according to one or 
more previous blood analysis, the 
latest analytical datac)  
 Compliance/failure criteria for 
Phase III 
 Documented information of each 
participant: exploration 
(anthropometric data, xanthomas 
and corneal arcus) and interview 
(drugs, family history, family tree), 
blood analysis.d 
 FH criteria (US Med‐Ped) and 39 
and the FCH (ISCIIIe) and.40 
 Diagnosis of dyslipidemia 
    
 
DCH: Digital clinical history.  
a Three or more phone calls on different days and time slots.  
b Researchers: medical specialists in internal medicine (n = 7), family medicine (n = 4) and endocrinology (n = 2).  
c Phase II—the latest analytical data: fasting glycaemia (mg/dL), glomerular filtration rate (GFR) (mL/min), uric acid (mg/dL), total 
cholesterol (TC) (mg/dL), triglycerides (TG) (mg/dL), low‐density lipoprotein (LDL‐C) (mg/dL), high‐density lipoprotein (HDL‐C) 
(mg/dL), creatinine (mg/dL).  
d Phase III—blood analysis: haemoglobin (g/dL), leucocytes (×109/L), platelets (×109/L), glucose (mg/dL), urea (mg/dL), creatinine 
(mg/dL), uric acid, creatinine phosphokinase (CPK) (UI/L), thyroid‐stimulating hormone (TSH) (μUI/mL), haemoglobin A1C (%), 
albumin urine (micro: 20‐300/macro: >300), albumin/creatinine ratio, TC, HDL‐C, LDL‐C, TG, GPT/ALT (UI/L), GGT (mg/dL), 
GOT/AST (mg/dL), apolipoprotein A (mg/dL), apolipoprotein B (mg/dL), Anti‐Nuclear Antibodies (AAN) (negative/positive titre), 
protein electrophoresis‐serum (normal/monoclonal peak).  
e Instituto de Salud Carlos III.  
  
Two training sessions supported by printed material to homogenise the data collection criteria were 
performed before Phases II and III, where all 13 researchers participated. 
 
The most recent available blood analysis within the last year was used for Phase II. If not available, a 
blood sample was drawn. 
 
A family tree of the participant that included all first degree relatives (parents, siblings and children) 
was constructed for the diagnosis of familial dyslipidemia (Phase III). Sources of data were the patients 
themselves and the medical records of their relatives and information on cardiovascular events. A lipid 
profile was obtained. 
 
Every single diagnosis was subsequently reviewed by a panel composed by the head researcher and at 
least five of the coresearchers. There were seven of these sessions during Phase III where agreement 
between the diagnosis of the coresearcher and the panel was assessed and a final decision was 
determined. The panel had full access to the digital clinical records during this process. All sessions were 
held in the central building of the public health administration in Galicia. 
 
All the reported cases of ASCVD in this paper were confirmed by two experts (one neurologist and 
one cardiologist). 
 




: Referred only to diagnosed and treated by reviewing the clinical digital history 
(CDH).  
 
Type 2 Diabetes mellitus
12
: Documented serum fasting glucose ≥126 mg/dL (7.0 mmol/L) on two 
separate tests or glycosylated haemoglobin (HbA1c) ≥6.5% or on treatment with antidiabetic drugs.  
 
Dyslipidemia: All participants that meet one or more of the following criteria: Any blood analysis 
(old/current) with TC ≥240 mg/dL or total TG ≥150 mg/dL or LDL‐C ≥ 160 mg/dL or high‐density 
lipoprotein cholesterol (HDL‐C) <50 mg/dL (women) and <40 mg/dL (men).  
 
Atherosclerotic cerebrovascular disease (CeVD): the following two conditions were required in the 
absence of atrial fibrillation:  
 
 Symptoms compatible as defined by the MONICA project (monitoring trends and determinants in 
cardiovascular disease)
13
: alteration of brain function with focal (or global) signs lasting more than 
24 h without other apparent vascular cause.  
 Image of stroke (computed tomography [CT] or magnetic resonance imaging [MRI]) or image of 
carotid‐vertebral atheromatosis with/without significant stenosis (Doppler ultrasound, CT 
angiography). 
 
Transient ischaemic stroke: focal neurological signs or symptoms with full recovery in less than 24 h 
and image of carotid‐vertebral atherosclerotic with/without significant stenosis (Doppler ultrasound, CT 
angiography).  
  
Coronary heart disease: presence of any of the following:  
 
 Acute coronary syndrome without ST‐segment elevation (NSTE) unstable angina or non‐Q AMI.14 
 Acute coronary syndrome with ST‐segment elevation (STEMI)15 
 
Peripheral artery disease (PAD): presence of any of the following:  
 
 Surgery or angioplasty of the lower extremities. 
 If angiography showed at least a stenotic lesion greater than 50% and/or aneurysm. 
 If the index ankle/brachial pressure was less than 0.9 with typical symptoms. 
 
Chronic kidney disease (CKD)
16
: presence of kidney damage or decreased glomerular filtration rate 
below 60 mL/min/1.73 m
2
 for 3 or more months, regardless of the cause that produces it.  
 
Atherosclerotic cardiovascular disease: personal history of at least one of the following three criteria:  
 
 Atherosclerotic cerebrovascular disease 
 Transient ischaemic stroke 
 Peripheral arterial disease 
 Coronary heart disease 
 
Familial dyslipidemia with autosomal dominant inheritance pattern (FDAD)
17
: At least 50% of first 
degree relatives subjects meet criteria of dyslipidemia.  
2.2 Statistical analysis 
Descriptive statistical analysis was performed. Qualitative variables were expressed as percentages 
and confidence intervals of 95%. The chi‐squared test was used with the Yates’ correction for continuity 
for the comparison between groups in qualitative variables. P‐values of <0.05 were regarded as 
statistically significant. An adjustment of rates was made with the direct method to estimate the 
prevalence of different conditions by sex, using the population of reference (Galicia) of the year 2012 as 
the standard population stratified in six age groups (18‐29, 30‐39, 40‐49, 50‐59, 60‐69, ≥70 years). This 
adjustment was done to correct the sample imbalance found in the group of women. The major diversions 
with regard to the population appear in the group of medium age (30‐39 years [+4.8%], 40‐49 years 
[+3.2%] and 50‐49 years [+2.9%]) and in the group of elders (70‐79 years [−3.4%] and ≥80 years 
[−4.9%]).  
 




 v.18 (SPSS Inc.; 
Chicago, IL, USA).  
2.3 Ethics 
This study was approved by the Clinical Research Ethics Committee of Galicia. 
 
Access to the medical records of the participants and their relatives through the DCH was expressly 
authorised (and saved as a voice record) by those participants for their best care. In addition, there was an 
electronic record of the reason for access to clinical information. 
 
Newly diagnosed cases of dyslipidemia were reported and referred to their primary care physician, 
including information on the implications for the family when corresponding. 
  
3 RESULTS 
A detailed flow chart with participation rates is shown in Figure 1. The participation rate in Phase I 
(89.5%) refer to those selected of whom contact was made and that meet the inclusion criteria. 
Information was completed by 93% of participants in Phase II (n = 933). Of these, 56.5% (n = 527) of the 
participants had dyslipidemia and met any of the criteria established by the GALIPEMIAS study to 
further evaluate their lipid alteration in the next phase. In Phase III, the researchers personally contacted 
each participant by telephone and/or letter to solicit a personal interview and physical examination. 
Participation rate in this phase was 71.5%, achieving 374 interviews. The lipid profile could not be 
evaluated because of insufficient familial data in only 32 cases, so that in 342 cases (91.4%), full 
information was obtained. It was determined that there was no dyslipidemia in 25 cases and in another 12 
cases there was not familial dyslipidemia (75% were related to obesity and 25% were other factors such 
as pregnancy, diabetes or alcoholism). Finally, a prevalence of familial dyslipidemia was observed in 
30.4% of the population. Of these, a percentage of 58.0% (CI 95% = 52.5‐63.9) was familial dyslipidemia 




Figure 1 Flow chart of participants. aWrong or nonexistent phone numbers: numbers of other subjects, fax numbers, nonexistent 
numbers. bNo telephone contact after three phone calls on different days and time slots. cRefusals to facilitate contact with the 
selected subject: families or couples who refuse to facilitate contact with the selected subject. dFailure inclusion criteria: deaths, 
neurodegenerative diseases, living in geriatric hospitals, embarked, living in another autonomous community. eNo contact (II and III 
phase) after two or more phone calls and an ordinary letter. Familial dyslipidemia: fautosomal dominant dyslipidemia (combined 
familial hyperlipidemia; familial autosomal dominant hypercholesterolemia; familial hipercolesterolaemia with Med‐Ped score ≥8; 
familial hypertriglyceridemia (IV)). gOther dyslipidemia (other familial dyslipidemia; no familial dyslipidemia)  
 
  
Table 2 shows certain characteristics of the studied sample as descriptive results obtained from the 
review of clinical digital history (personal history of disease, cardiovascular drugs and antidiabetic drugs). 
Distribution and comparison are detailed by gender. 
Table 2. Personal history of disease and current cardiovascular and antidiabetic drug intake 
 
Total (n = 1003) Men (n = 461) Women (n = 542) P‐value  
     
Age (M ± SD) 46.7 ± 15.0 46.1 ± 15.3 45.4 ± 15.7 0.48 
Personal history of disease (collected from HCD in Phase II) 
Hypertension 18.2 (15.8‐20.7) 18.7 (15.0‐22.3) 17.9 (14.6‐21.2) 0.76 
Smoking habit 10.1 (8.2‐12.0) 13.7 (10.4‐16.9) 7.0 (4.8‐9.3) <0.001  
Aortic aneurysm 0.1 (0.003‐0.6) — 0,2 (0.005‐1.0) — 
CKD 1.1 (0.4‐1.8) 1.7 (0.4‐3.0) 0.6 (1.1‐1.6) 0.07 
PAD 0.9 (0.3‐1.5) 1.7 (0.4‐3.0) 0,2 (0.005‐1.0) 0.02  
Coronary heart disease 2.0 (1.1‐2.9) 3.3 (1.5‐5.0) 0.9 (0.3‐2.1) 0.02  
Atherosclerotic cerebrovascular disease 0.8 (0.2‐1.4) 1.3 (0.2‐2.4) 0.4 (0.5‐1.3) 0.2 
Cardiovascular and antidiabetic drugs 
Lipid‐lowering drugs 3.9 (2.8‐5.3) 5.9 (3.9‐8.4) 2.2 (1.1‐3.8) 0.003  
Statins 14.7 (12.6‐17.1) 16.0 (12.8‐19.7) 13.7 (10.9‐16.8) 0.33 
Antidiabetic drugs (oral and insulin) 4.9 (3.6‐6.4) 7.2 (5.0‐9.9) 4.8 (3.2‐6.9) 0.11 
Insulin 1.4 (0.8‐2.3) 2.2 (1.1‐4.0) 0.7 (0.2‐1.9) 0.05 
Anti‐platelet 6.0 (4.6‐7.6) 8.2 (5.9‐11.1) 4.1 (2.6‐6.1) 0.005  
ACEIs and AIIRA II 14.0 (11.9‐16.3) 14.8 (11.6‐18.3) 13.3 (10.5‐16.4) 0.5 
Anti‐coagulants (Sintrom®)  1.1 (0.6‐1.9) 1.5 (0.6‐3.1) 0.7 (0.2‐1.9) 0.24 
Beta‐blockers 3.2 (2.2‐4.5) 4.1 (2.5‐6.4) 2.4 (0.1‐1.6) 0.12 
Calcium antagonist 4.1 (3.0‐5.5) 5.5 (3.6‐8.0) 3.0 (1.7‐4.8) 0.049  
Diuretics 5.0 (3.7‐6.6) 4.6 (2.9‐7.0) 5.4 (3.6‐7.6) 0.56 
     
 
ACEIs: angiotensin‐converting enzyme inhibitors; AIIRA: Angiotensin receptor antagonist; CKD, chronic kidney disease; PAD: 
peripheral arterial disease.  
Data expressed prevalence (95% confidence interval) except age.  
P‐value (statistical significance 0.05) of men versus women. In bold: p‐value<0.05  
Weight and height were measured in the subjects participating in phase III and their body mass index 
(BMI) was calculated. For all subjects, the mean and SD BMI was 28.11 ± 4.38, in women was 
27.8 ± 5.04 and in men was 28.41 ± 3.56. 
 
Table 3 shows the crude and adjusted prevalences of the different conditions detected in any blood 
analysis (data from DCH). It highlights that 9.2% of participants had diabetes and the incidence was 
higher in men compared with women (P < 0.005). Over 20% had at least two fasting blood tests with 
impaired fasting glucose (≥100 mg/dL). About altered GFR, the 9.9% of subjects had at least one 
analytical test altered (<60 mL/min), and 16.2% of subjects had at least one blood analysis with uric acid 
≥7 mg/dL, which was significantly higher among men (23.6%).  
  
Table 3. Prevalence of selected conditions by gender 
 
Total (n = 933)  Men (n = 413)  Women (n = 520) 
P‐value  
CR AR (95% CI) N  CR AR (95% CI) N  CR AR (95% CI) N 
             
Diabetes 7.0 9.2 (6.8‐12.3) 933  10.2 11.8 (8.2‐16.5) 413  4.4 5.9 (3.3‐10.2) 520 0.001  
IFG 17.5 20.5 (17.0‐24.6) 933  22.3 23.5 (18.6‐29.5) 413  13.7 17.8 (13.0‐24.1) 520 0.001  
AGFR 6.8 9.9 (7.3‐13.2) 932  7.7 9.6 (6.4‐14.1) 413  6.0 10.2 (6.2‐15.9) 519 0.28 
Hyperuricemia 13.2 16.2 (13.0‐20.0) 930  21.8 23.6 (18.6‐29.7) 412  6.4 9.1 (5.6‐14.2) 518 <0.0001  
TC ≥200 mg/dL 60.0 60.8 (55.3‐66.9) 932  61.7 59.7 (52.2‐68.2) 412  58.7 62.8 (54.4‐72.5) 520 0.35 
TG ≥150 mg/dL 31.3 33.1 (28.9‐37.9) 932  39.3 38.3 (32.3‐45.3) 412  25.0 29.6 (23.6‐37.1) 520 <0.0001  
TC ≥240 mg/dL 32.3 34.5 (30.2‐39.4) 932  32.0 32.3 (26.7‐38.0) 412  32.5 36.3 (29.9‐44.2) 520 0.88 
cLDL ≥160 mg/dL 25.2 27.1 (23.3‐31.6) 926  28.7 29.5 (23.1‐36.0) 408  22.8 24.8 (19.6‐31.3) 518 0.05 
cHDL <50 mg/dL ♀/40 mg/dL ♂  23.8 25.7 (21.9‐30.0) 925  25.6 26.6 (21.4‐32.9) 407  22.4 24.8 (19.5‐31.5) 518 0.26 
Any criteria of lipid disorder 56.5 58.9 (53.4‐65.1) 933  63.2 62.9 (55.1‐71.7) 413  51.2 56.2 (48.2‐65.7) 520 <0.0001  
Familial dyslipidemia with ADIP 19.0 19.7 (16.4‐23.0) 933  22.8 21.8 (17.2‐26.4) 413  16.0 18.6 (13.6‐23.5) 520 0.009 
             
 
Data expressed: CR: crude rate; AR: adjusted/standardised rate to the Galician population by six age groups (18‐29, 30‐39, 40‐49, 
50‐59, 60‐69 ≥ 70 years old); N: sample from which data are available; P‐value (statistical significance 0.05) of men versus women. 
In bold: p‐value <0.05.  
IFG: impaired fasting glucose (two blood test fasting blood glucose ≥100 mg/dL <126 mg/dL); AGFR (altered glomerular filtration 
rate): any blood analysis with glomerular filtration rate <60 mL/min; Hyperuricemia: any blood analysis with uric acid ≥7 mg/dL; 
Any criteria of lipid disorder (any blood analysis (old or current) with TC ≥240 mg/dL or TG ≥150 mg/dL or cLDL ≥160 mg/dL or 
cHDL <50 mg/dL (♀)/<40 mg/dL (♂)). ADIP: autosomal dominant inherit pattern.  
In relation to lipid profile, 60.8% of our study population had a total cholesterol ≥200 mg/dL, with 
34.5% over 240 mg/dL. Approximately 33.1% of the subjects had triglycerides ≥150 mg/dL, and 27.1% 
had LDL cholesterol ≥160 mg/dL and both were significantly higher among men. Approximately 26.6% 
of men had HDL‐C levels lower than 50 mg/dL, and 24.8% of women had HDL‐C levels lower than 
40 mg/dL. 
 
Patients with FDAD showed, with respect to patients with other dyslipidemias, a more unfavourable 
lipid profile with significantly higher mean levels of TC (214 vs 198 mg/dL), LDL‐C (132 vs 124 mg/dL) 
and TG (148 vs 103). However, the percentage of patients treated with statin (30.7% vs 27.4%) or statins 
plus ezetimibe (4.5% vs 3.2%) as well as the proportion of patients with LDL‐C < 100 mg/dL (20.2 vs 
20.6%) according to recommendations of clinical practice guidelines
19
 for patients with FDAD, was 
similar in both groups (Table 4).  
  
Table 4. Degree of lipid control in subjects with dyslipidemia 
 
Familial dyslipidemia autosomal  
dominant (n = 176) 
 Other dyslipidemia (n = 141)  Alld (n = 317)   
P‐valuec 
N M (SD)   N M (SD)   N M (SD)   
           
TCa 174 214.2 (40.9)  140 198.6 (40.6)  314 207.2 (41.4)  0.0008  
TGa 174 148.0 (80.6)  138 103.3 (44.1)  312 128.2 (70.5)  0.0  
LDL‐Ca 168 132.5 (35.4)  138 124.6 (33.3)  306 129.0 (34.6)  0.05 
HDL‐Ca 171 54.2 (15.6)  138 53.9 (15.7)  309 54.1 (15.6)  0.9 
 N  % (95% CI)   N  % (95% CI)   N  % (95% CI)    
LDL‐C < 100b 168 20.2 (13.9‐26.6)  138 21.0 (13.9‐28.2)  306 20.59 (12.8‐28.3)  0.98 
LDL‐C < 70b,e 7 14.3 (0.4‐57.9)  9 22.2 (2.8‐60.0)  16 18.8 (1.0‐62.2)  0.8 
Statinsb 176 30.7 (23.6‐37.8)  141 23.4 (16.1‐30.7)  317 27.4 (19.0‐35.8)  0.2 
Statins & Ezetimibab 176 4.5 (1.2‐7.9)  141 1.4 (0.02‐8.2)  317 3.2 (0.2‐6.5)  0.2 
           
 
a Data expressed : N = sample from which data are available, Mean (SD) = mean and standard deviation.  
b Data expressed: N = sample from which data are available, % (95% CI) = Prevalence (95% confidence interval).  
c P‐value (statistical significance 0.05) of subjects with familial dyslipidemia autosomal dominant versus subjects with other familial 
dyslipidemia.  
d All: All subjects with confirmed dyslipidemia.  
e Data expressed subjects with autosomal dominant dyslipidemia and diagnosed ASCVD with LDL‐C < 70 mg/dL. In bold: p‐value 
<0.05  
Figure 2 shows the corrected prevalence of ASCVD diagnosed from the DCH. An overall corrected 
prevalence of 5.1 (95% CI = 3.1‐7.2) was found with higher prevalence among men with 7.3% (95% 
CI = 4.2‐10.4) than for women (prevalence of 2.6% and CI 95% = 10.3‐5.0). An ascending pattern was 




Figure 2 Diagnosed atherosclerotic cardiovascular disease prevalences. *Corrected prevalences by age distribution (age: <40; 40‐
59; 60‐69; ≥70 years) in each gender in Galicia. **Corrected prevalences by sex distribution in each age group in Galicia. All: 
Corrected prevalences by age distribution for all subjects 
  
4 DISCUSSION 
The present study (GALIPEMIAS) conducted on a representative sample of the Galician population 
(northwestern Spain) shows that dyslipidemia was present in more than half of the participants (56.5%). 
More importantly, in regard to health policy and previously unreported findings, one out of every three 
dyslipidemia cases (33.7%) show an autosomal dominant inheritance pattern. It also shows that 5.1% of 
the sample population ≥18 years of age have suffered an episode of ASCVD. 
 
Prevalence of dyslipidemia in this study is similar to previous studies in Spain,
6,7,20
 some of which did 
not include the Galician population.
3 
Moreover, the prevalence of diabetes in our study (8.3%) is 
consistent with the results of previously published investigations,
21,22
 as well as the diabetes study
23
 that 
set in at 8%, about four points below the Spanish average. On the other hand, our investigation shows a 
prevalence of hypertension at 18.2%, which is lower than other investigations carried out in our country 
(25.5%‐42.6%)24,25; however, regarding this difference, it should be noted that we only collected 
previously diagnosed and treated hypertension. The studies above had a prevalence of 12.9% and 26.7%, 
respectively. Smoking prevalence was exceptionally low in our study (10.1%) when compared with 
Eurobarometer data for Spain (29%)
26
 or the 2012 Spanish National Health Survey (24%).
27 
Several 
aspects can explain such a difference. First, the fact that in Galicia the proportion of smokers is lower 
than the Spanish average as shown by a study through the Information System of Risk Behaviour 
(SICRI).
28 
Second, these studies have included people from 16 years of age and the younger age groups 
with a higher rate of smoking (23.8% in the 16‐24 age group vs 6.4% ≥65 years) are overrepresented. 
Finally, although our research for smoking data was collected by standardised survey, we do not rule out 
that occasional smokers have self‐declared as nonsmokers, which could be up to an additional 4%.29 
 
To our knowledge, no published studies have examined the prevalence of familial dyslipidemia with 
an autosomal dominant inheritance pattern in the general population. Since Goldstein
30
 reported in 1973 
that 54% of the 157 hyperlipidaemic survivors of a myocardial infarction had monogenic familial 
dyslipidemia and its global prevalence was estimated in the same paper at 0.6‐1%, there has been no 
research that addressed such an estimation.  
 
In our study, the degree of lipid control in patients with FDAD was very poor. In general, only one in 
five patients with FDAD had a target LDL‐C according to recommendations of clinical practice 
guidelines (<100 mg/dL). Despite these data, only 30% were being treated with statins and less than 5% 
were receiving combined treatment (statin plus ezetimibe). We consider a multifactorial origin for this 
unfavourable data that includes low level of awareness about FDAD between patients and health 
professionals and clinical inertia. 
 
Finally, we found no population‐based studies that have examined the prevalence of clinically relevant 
ASCVD by reviewing the medical records of all subjects included. Using this methodology, only limited 
approaches to a single vascular territory or age group detected a prevalence of 4% of acute myocardial 
infarction in a population over 65 years,
31
 7.3% rate of stroke (also embolic and haemorrhagic) in 
individuals ≥70 years old
32
 or 0.78% of symptomatic PAD (ankle/brachial index of <0.9 with symptoms 
or revascularisation) in the population aged 35‐79 years. Our partial data are consistent with those 
observations. In many population‐based research studies, cardiovascular disease data collection (not 
always ASCVD) was conducted through surveys, which resulted in a greater number of biases.
33,34 
  
4.1 Study limitations 
The main limitation of the study was obtaining the informed consent through telephone contact, which 
could have reduced the participation rate. To minimise this problem, the potential participants were 
informed of the affiliation of the researchers with public health administration (own service professionals, 
specialists in lipid disorders) as well as the personal and familial implications of a proper diagnosis. 
 
A letter was also sent to all primary care physicians attending the selected population to keep them 
informed of the purpose of the study and that it was being carried out in individuals of their population 
(because a patient might ask about the study to his doctor). 
 
The proportion of incorrect or nonexistent telephone numbers on the health card was very high (724 
confirmed errors from 2622 successfully contacted, 27.6% of all contacts). It was impossible to estimate 
what proportion of the uncontacted participants was because of errors in the information of the health 
card, but it must be very high (deceased, second homes, changes in address, etc.). These data will be 
useful for further studies and researchers that require this method as it is necessary to take this into 
account when obtaining and calculating the sample size. 
 
There was a deviation in the older group of women (≥70 years) in our sample with respect to the 
population (Galicia). There were fewer older women in the GALIPEMIAS study. In other cross‐sectional 
studies in which the incorporation of subjects was through telephone calls, the participation usually 
deviated to the opposite direction (greater number of older women), because of their availability at home. 
But in this case, we think that the underrepresented people correspond to the uncontacted subjects. 
 
Another possible reason would be the exclusion criteria in Phase I, such as neurodegenerative diseases 
or people living in geriatric hospitals in that that they could not participate in the personal interview of 
Phase III. This could have biased the sample in the older groups. In order to solve for this bias, a 
correction was made to weight the prevalence by age and gender groups. 
4.2 Study strengths 
One of the most important study strengths with the described methodology is the high participation 
obtained with the telephone calls to establish the sample and to obtain the informed consent (89.5%). 
 
Several studies have demonstrated the validity of the DCH for epidemiological studies. This source of 
information allows for both a historical view of the history of illness, laboratory values and medication 
and lowers the economic costs in collecting epidemiological data.
35-38 
 
The selection criteria established by the study based on scientific knowledge selected susceptible 
subjects from the general population based on four criteria (TC ≥240 mg/dL, TG ≥150 mg/dL, LDL‐
C ≥ 160 mg/dL and HDL‐C < 50 [women] <40 [men]), and a comprehensive review highlighted the 
family tree as a tool for diagnosing familial dyslipidemia. This study was subsequently endorsed by a 
panel of researchers in lipids that ensured the diagnosis. Other strengths include rigorous criteria for 
collecting data and conducting homogenisation sessions prior to the start of the study in order to ensure 
that the methodology for data collection was as similar as possible between all 13 researchers. 
  
5 CONCLUSION 
In summary, the GALIPEMIAS study shows that dyslipidemia is the most prevalent cardiovascular 
risk factor in our population with an autosomal dominant inheritance pattern in one of every three 
dyslipidemia cases. The percentage of FDAD patients with LDL‐C on target is low mostly because of the 
low use of statins. It also shows that 5.1% of the sample population ≥18 years of age have suffered an 
episode of ASCVD. 
 
No published studies have examined the prevalence of familial dyslipidemia with autosomal dominant 
inheritance pattern in the general population, so the next analysis of the GALIPEMIAS data will generate 
greater knowledge regarding this gap. 
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